Personalized treatment for pediatric Wilms tumor
Part of Cancer, Kidney & urinary clinical trials.
This study tailors treatment for children with Wilms tumor based on specific tumor features and risk factors. The goal is to give the right amount of therapy to each patient to minimize side effects while maintaining high cure rates.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Newly diagnosed with favorable histology Wilms tumor, stages I to IV
- Must be enrolled in the screening study APEC14B1 before joining this trial
- Must have a central review confirming the diagnosis and risk classification
- If receiving chemotherapy, liver and heart function must meet specified criteria
- No prior chemotherapy or radiation for this cancer
- Must agree to use effective contraception if sexually active (for reproductive potential)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests combination chemotherapy for children with certain types of Wilms tumor—either newly diagnosed diffuse anaplastic Wilms tumor or favorable Wilms tumor that has come back. The goal is to see how well the treatment controls the tumor and is tolerable for children.
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
This trial studies a specific type of radiation (proton beam) given to the abdomen after surgery and/or chemotherapy in children and young people with newly diagnosed Wilms tumor. The goal is to improve cancer control while carefully targeting radiation to the right stage of disease.
This Phase 1/2 trial studies metronomic (very low, steady) chemotherapy taken by mouth or through a feeding tube for children with Wilms tumor that has come back or not responded to earlier treatment. It aims to shrink measurable tumors with better long-term tolerability than standard chemotherapy.
Hear when a new Stage I Mixed Cell Type Kidney Wilms Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.